A Clinical Trial To Compare The Efficacy And Safety Of Imeglimin ( A Novel Anti-Diabetic agent) With Existing Anti-Diabetic Agents In Newly Diagnosed Type 2 Diabetes Patients.
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2023/11/060291
- Lead Sponsor
- Government Medical College, Jammu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Age: =18-60 years (both male and female).
2.Newly diagnosed type 2 diabetes mellitus (T2DM) patients (FBG =126mg/dl, PPBS = 200mg/dl with symptoms like polyuria, polydipsia and polyphagia, 2 hours plasma glucose OGTT = 200mg/dl and HbA1C = 6.5%) diagnosed within 6 months from starting of this study and attending the Endocrinology outpatient department (OPD).
3.HbA1C 6.5-8 %
4.Those who are willing to participate and give their consent shall be included in the study.
1.Age <18 years and > 60 years
2.Type 1 Diabetes Mellitus patients.
3.T2DM patients having renal dysfunction with eGFR = 45ml/min.
4.T2DM patients with hepatic impairment with child Turcotte Pugh (CTP) class C.
5.Steroid induced T2DM/ Syndromic diabetes.
6.Pregnant/ lactating women with diabetes.
7.Patients not able to tolerate the therapy or presented with adverse drug reaction.
8.Unwilling to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method